BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• 

  Press Releases

  Viral Hepatitis Market Estimated to Reach a CAGR of 2.69% during 2024-2034, Impelled by Widespread Adoption of Antiviral Medications

  July 16, 2024

   · 

  12 min read
• 

  Press Releases

  Vulvar Cancer Market Estimated to Reach a CAGR of 4.69% during 2024-2034, Impelled by Increased Application of Hormonal Drug Therapies

  July 16, 2024

   · 

  11 min read
• Drug Development

  Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis (ALS)

  July 16, 2024

   · 

  4 min read
• FDA

  SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to SLS009 for the Treatment of Pediatric Acute Myeloid Leukemia

  July 16, 2024

   · 

  5 min read
• FDA

  Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism

  July 16, 2024

   · 

  6 min read
• News

  Alkeus Pharmaceuticals Appoints Tamara Dillon as Chief Human Resources Officer

  July 16, 2024

   · 

  2 min read
• Drug Development

  FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)

  July 16, 2024

   · 

  4 min read
• Business

  CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

  July 16, 2024

   · 

  1 min read
• FDA

  Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance

  July 16, 2024

   · 

  10 min read
• Drug Development

  CSL Behring Announces Positive Reimbursement Decision in Canada for HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B

  July 16, 2024

   · 

  6 min read